PharmaShots | Incisive News in 3 Shots

Subscribe Now

Amicus Therapeutics

Amicus Therapeutics’ Pombiliti (cipaglucosidase alfa-atga) + Opfolda Receive the US FDA’s Approval for Pompe Disease

Amicus Therapeutics’ Pombiliti (cipaglucosidase alfa-atga) + Opfolda Receive the US FDA’s Approval for Pompe Disease

September 29, 2023

Amicus Therapeutics’ Pombiliti + Opfolda Receive EC’s Approval for the Treatment of Pompe Disease

Amicus Therapeutics’ Pombiliti + Opfolda Receive EC’s Approval for the Treatment of Pompe Disease

June 25, 2023

Amicus Therapeutics Receives EMA’s CHMP Positive Opinion Recommending Marketing Authorization of Opfolda (miglustat) for Late-Onset Pompe Disease

Amicus Therapeutics Receives EMA’s CHMP Positive Opinion Recommending Marketing Authorization of Opfolda (miglustat) for Late-Onse...

April 26, 2023

Amicus Therapeutics’ Pombiliti (cipaglucosidase alfa) Receives EC’s Approval for the Treatment of Late-Onset Pompe Disease

Amicus Therapeutics’ Pombiliti (cipaglucosidase alfa) Receives EC’s Approval for the Treatment of Late-Onset Pompe Disease

March 27, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us